Sonnet BioTherapeutics Holdings, Inc.
SONNHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $18,626 | $147,805 | $349,943 | $483,626 | — |
| Operating income | −$15.8M | −$11.8M | −$18.8M | −$29.7M | −$25.1M | −$24.2M |
| Net income | −$16.0M | −$7.4M | −$18.8M | −$29.7M | −$25.0M | −$24.3M |
| Total assets | $14.9M | $2.8M | $5.4M | $5.8M | $29.0M | $8.0M |
| Total liabilities | $4.1M | $3.3M | $5.7M | $8.4M | $6.7M | $5.0M |
| Equity | $10.8M | −$485,739 | −$225,980 | −$2.5M | $22.3M | $3.0M |
| EPS (diluted) | $-3.95 | $-11.35 | $-145.13 | $-150.52 | $-14.25 | — |
| Shares out. | 1 | 3.0M | 3.1M | 7.9M | 60.3M | 17.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1584.4%
- Net margin
- −1601.1%
- Return on equity
- −148.4%
- Return on assets
- −107.6%
- Return on capital (ROCE)
- −146.9%
- Liabilities / assets
- 27.5%
- Debt / equity
- 0.38×
- Book value / share
- $10787579.00
- Revenue growth (YoY)
- 5268.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -29.15distress
- Accruals / assets
- −21.4%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2020
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2016
- NT 10-Qmissed a reporting deadline ↗May 15, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2015
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2013
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Republic Digital Opportunistic Digital Assets Master Fund, Ltd.Passive (13G)Jul 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kenney Richard TOfficer — Chief Medical Officer | Dec 2, 2025 | D | 9,374 | — |
| Mcandrew Stephen JOfficer — Chief Business Officer | Dec 2, 2025 | D | 6,446 | — |
| Griffith Donald J.Officer — Chief Financial Officer | Dec 2, 2025 | D | 10,375 | — |
| Mcneill LoriDirector | Dec 2, 2025 | D | 4,394 | — |
| Dexter SusanDirector | Dec 2, 2025 | D | 9,643 | — |
| Rao RaghuOfficer — Chief Executive Officer | Dec 2, 2025 | D | 22,356 | — |
| Cini John K.Director | Dec 2, 2025 | D | 14,116 | — |
| Bhatt NaileshDirector | Dec 2, 2025 | D | 10,547 | — |
| Dyrness Albert D.Director | Dec 2, 2025 | D | 4,537 | — |
| Dyrness Albert D.Director | Jul 11, 2023 | Grant | 4,000 | — |
| Rao RaghuOfficer — Interim CEO | Jul 11, 2025 | Grant | 20,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Nov 28, 2025 | 1.9M | 2.6 | -13.1% |
| Nov 14, 2025 | 2.2M | 2.6 | -14.9% |
| Oct 31, 2025 | 2.5M | 4.8 | +15.7% |
| Oct 15, 2025 | 2.2M | 4.5 | +1.4% |
| Sep 30, 2025 | 2.2M | 1.4 | -3.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder vote · Regulation FD disclosureDec 3, 2025
- Other material eventDec 2, 2025
- Regulation FD disclosureNov 18, 2025
- Shareholder voteSep 29, 2025
- Director / officer changeAug 1, 2025
- Other material eventJul 25, 2025
- Other material eventJul 18, 2025
- Entered a material agreement · Unregistered equity sale · Director / officer change · Amended charter or bylaws · Regulation FD disclosure · Other material eventJul 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.